products.","type":"text"}, {"identifier":" anf-body- 41","inlineTextStyles":[{"range": {"length":258, "start":0},"textsStyle":" anf-ts- I"},{"range™:{"length":258,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"In restricting access to Revlimid and Thalomid, Celgene relied on a federal requirement that the distribution of those drugs be tightly regulated because of their dangerous side effects under a program known as Risk Evaluation and Mitigation System, or REMS.", "type": "text"}, {"components": [{"caption":"Elaine Kodish, who lives in Los Angeles, said she pays $785 a month for Revlimid, a drug produced by Celgene that helps treat her multiple myeloma. Emily Berl for The New York Times", "captionComponent": {"text":"Elaine Kodish, who lives in Los Angeles, said she pays $785 a month for Revlimid, a drug produced by Celgene that helps treat her multiple myeloma. Emily Berl for The New York Times"},"identifier™:"100000006098034 Sba8b8041267d", "imageIdentifier":"eee32d2f6bc7b8b dbJVabad5d6cab07a43", "Layout": "fullbleed- image", "role":"photo", "type": "scalable image"}, {"identifier":" anf-caption-— 4","inlineTextsStyles": [{"range":{"Llength":34,"start":147},"textsStyle": "photo- credit"}],"Llayout":"default-caption", "role": "caption", "text":"Elaine Kodish, who lives in Los Angeles, said she pays $785 a month for Revlimid, a drug produced by Celgene that helps treat her multiple myeloma. Emily Berl for The New York Times ","type™:"text"}],"identifier":" anf-container-3", "layout": "image- container", "role":"container", "type":"container"}, {"identifier":" anf-body- 42","inlineTextStyles":[{"range":{"length":111,"start":0},"textsStyle":" anf-ts- i"}, {"range"™:{"length":111,"start":0},"textStyle":" anf-ts-1"}],"layout":"default-— body", "role":"body", "text":"Congress expressly prohibited drug companies from using these programs to block or delay generic drug approval.","type":"text"}, {"identifier":" anf-body- 43","“inlin